Key Points
- Vaxcyte CFO Andrew Guggenhime sold 10,000 shares on July 6 at an average price of $57.28, totaling $572,800. The sale reduced his direct holdings by 8.74% and was made under a pre-arranged Rule 10b5-1 plan.
- The CFO also sold 10,000 shares on June 18 at an average price of $53.00, indicating a pattern of recent insider selling.
- Vaxcyte shares were down about 2.4% in the session, while the company continues to draw mixed analyst views with a Moderate Buy consensus and a $86 average price target.
Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 2,250 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total transaction of $126,742.50. Following the sale, the chief operating officer owned 156,760 shares in the company, valued at approximately $8,830,290.80. This trade represents a 1.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Jim Wassil also recently made the following trade(s):
- On Monday, June 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $49.52, for a total value of $111,420.00.
- On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.83, for a total value of $127,867.50.
Vaxcyte Stock Performance
Shares of PCVX opened at $57.60 on Tuesday. Vaxcyte, Inc. has a 1 year low of $29.08 and a 1 year high of $65.00. The firm has a fifty day moving average of $52.21 and a 200-day moving average of $53.47. The company has a market cap of $8.32 billion, a price-to-earnings ratio of -8.37 and a beta of 1.22.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.56). During the same quarter in the previous year, the company posted ($1.04) EPS. Analysts predict that Vaxcyte, Inc. will post -7.91 EPS for the current year.
Analysts Set New Price Targets
A number of research analysts have recently commented on PCVX shares. Weiss Ratings reissued a "sell (d-)" rating on shares of Vaxcyte in a report on Wednesday, April 8th. Wall Street Zen lowered shares of Vaxcyte from a "sell" rating to a "strong sell" rating in a research report on Tuesday, April 28th. Finally, Jefferies Financial Group reissued a "buy" rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Vaxcyte has an average rating of "Moderate Buy" and a consensus price target of $86.00.
Read Our Latest Report on Vaxcyte
Institutional Trading of Vaxcyte
A number of large investors have recently added to or reduced their stakes in the business. Empowered Funds LLC grew its position in Vaxcyte by 111.8% in the first quarter. Empowered Funds LLC now owns 9,692 shares of the company's stock worth $563,000 after buying an additional 5,116 shares during the last quarter. Seven Fleet Capital Management LP lifted its position in shares of Vaxcyte by 406.4% during the 1st quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company's stock valued at $7,464,000 after acquiring an additional 103,085 shares during the last quarter. DV Trading LLC bought a new stake in shares of Vaxcyte during the 1st quarter worth $1,162,000. Bank of America Corp DE boosted its stake in shares of Vaxcyte by 73.4% during the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company's stock worth $70,711,000 after acquiring an additional 515,209 shares in the last quarter. Finally, Stempoint Capital LP acquired a new position in shares of Vaxcyte in the 1st quarter worth $3,432,000. 96.78% of the stock is currently owned by institutional investors.
About Vaxcyte
(
Get Free Report)
Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company's platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.
Vaxcyte's lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
